To enhance the infiltration of CAR-T cells to tumor site experiments, for instance, anti-angiogenic therapy targeting VEGF, CD276, and combination with CAR-T cells are being evaluated (Daenen et al., 2009[21]; Yang et al., 2018[123]) and FAP-CAR-T cells reducing tumor fibroblast numbers and thus inhibiting tumor growth (Lim et al., 2020[60]; Moon et al., 2018[81]). This evidence concerns the gene CD276 and neoplasm.